


A82

(11) **EP 0 990 437 B1**(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
20.11.2002 Bulletin 2002/47

(51) Int Cl.7: **A61K 9/00, A61K 9/12,**
A61K 31/56, A61K 31/135

(21) Application number: **99204248.1**

(22) Date of filing: **04.12.1992**

(54) **Aerosol compositions**

Aerosolpräparate

Compositions pharmaceutiques sous forme d'aérosol

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: **12.12.1991 GB 9126378**
12.12.1991 GB 9126405
06.02.1992 GB 9202522

(43) Date of publication of application:
05.04.2000 Bulletin 2000/14

(60) Divisional application:
00202961.9 / 1 066 828

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
96202592.0 / 0 756 868
92924667.6 / 0 616 523

(73) Proprietor: **GLAXO GROUP LIMITED**
Greenford, Middlesex UB6 ONN (GB)

(72) Inventors:

- **Marriott, Rachel Ann**
San Diego, CA 92129 (US)
- **Taylor, Anthony James**
Ware, Hertfordshire SG12 0DP (GB)
- **Wyatt, David Andrew**
Ware, Hertfordshire SG12 0DP (GB)

(74) Representative: **Teuten, Andrew John et al**
GlaxoSmithKline
Corporate Intellectual Property (CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
WO-A-91/11173 **WO-A-91/11496**
WO-A-92/00061 **WO-A-92/08447**

EP 0 990 437 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

1

EP O 990 437 B1

2

Description

[0001] This invention relates to aerosol formulations of use for the administration of medicaments by inhalation.

[0002] The use of aerosols to administer medicaments has been known for several decades. Such aerosols generally comprise the medicament, one or more chlorofluorocarbon propellants and either a surfactant or a solvent, such as ethanol. The most commonly used aerosol propellants for medicaments have been propellant 11 (CCl_3F) and/or propellant 114 ($\text{CF}_2\text{ClCF}_2\text{Cl}$) with propellant 12 (CCl_2F_2). However these propellants are now believed to provoke the degradation of stratospheric ozone and there is thus a need to provide aerosol formulations for medicaments which employ so called "ozone-friendly" propellants.

[0003] A class of propellants which are believed to have minimal ozone-depleting effects in comparison to conventional chlorofluorocarbons comprise fluorocarbons and hydrogen-containing chlorofluorocarbons, and a number of medicinal aerosol formulations using such propellant systems are disclosed in, for example, EP 0372777, WO91/04011, WO91/11173, WO91/11495 and WO91/14422. These applications are all concerned with the preparation of pressurised aerosols for the administration of medicaments and seek to overcome the problems associated with the use of the new class of propellants, in particular the problems of stability associated with the pharmaceutical formulations prepared. The applications all propose the addition of one or more of adjuvants such as alcohols, alkanes, dimethyl ether, surfactants (including fluorinated and non-fluorinated surfactants, carboxylic acids, polyethoxylates etc) and even conventional chlorofluorocarbon propellants in small amounts intended to minimise potential ozone damage.

[0004] Thus, for example EP 0372777 requires the use of 1,1,1,2-tetrafluoroethane in combination with both a cosolvent having greater polarity than 1,1,1,2-tetrafluoroethane (e.g. an alcohol or a lower alkane) and a surfactant in order to achieve a stable formulation of a medicament powder. In particular it is noted in the specification at page 3, line 7 that "it has been found that the use of propellant 134a (1,1,1,2-tetrafluoroethane) and drug as a binary mixture or in combination with a conventional surfactant such as sorbitan trioleate does not provide formulations having suitable properties for use with pressurised inhalers". Surfactants are generally recognised by those skilled in the art to be essential components of aerosol formulations, required not only to reduce aggregation of the medicament but also to lubricate the valve employed, thereby ensuring consistent reproducibility of valve actuation and accuracy of dose dispensed. Whilst WO91/11173, WO91/11495 and WO91/14422 are concerned with formulations comprising an admixture of drug and surfactant, WO91/04011 discloses medicinal aerosol formulations

in which the particulate medicaments are pre-coated with surfactant prior to dispersal in 1,1,1,2-tetrafluoroethane.

[0005] WO92/08447 discloses formulations comprising a drug which is surface coated with a surfactant and a hydrofluorocarbon propellant. WO91/11496 discloses use of HFA227 as an alternative propellant optionally in admixture with another propellant gas. US3,320,125 discloses CFC-containing pharmaceutical aerosol formulations in which use of sorbitan trioleate is avoided by use of propellant 11 at a concentration of 5-50%.

[0006] We have now surprisingly found that, in contradistinction to these teachings, it is in fact possible to obtain satisfactory dispersions of certain medicaments in fluorocarbon or hydrogen-containing chlorofluorocarbon propellants such as 1,1,1,2-tetrafluoroethane without recourse to the use of any surfactant or cosolvent in the composition, or the necessity to pre-treat the medicament prior to dispersal in the propellant.

[0007] There is thus provided in one aspect of the invention a pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation characterised in that it consists essentially of particulate fluticasone propionate as medicament and 1,1,1,2-tetrafluoroethane as propellant and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation. By "free of surfactant" is meant formulations which contain no significant amounts of surfactant, for example less than 0.0001% by weight of the medicament.

[0008] There is also provided a pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation characterised in that it consists of particulate fluticasone propionate and 1,1,1,2-tetrafluoroethane wherein said fluticasone propionate is present in an amount of 0.01% to 1% w/w relative to the total weight of the formulation.

[0009] As another aspect the present invention provides use of a pharmaceutical aerosol formulation as hereinbefore defined for the manufacture of a medicament for the treatment of respiratory disorders.

[0010] The particle size of the particulate (e.g. micronised) medicament should be such as to permit inhalation of substantially all of the medicament into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and preferably in the range 1-10 microns, e.g. 1-5 microns.

[0011] The propellant for use in the invention is 1,1,1,2-tetrafluoroethane which has a sufficient vapour pressure to render it effective as a propellant.

[0012] It is desirable that the formulations of the invention contain no components which may provoke the degradation of stratospheric ozone. In particular it is desirable that the formulations are substantially free of chlorofluorocarbons such as CCl_3F , CCl_2F_2 and CF_3CCl_3 .

[0013] Further, formulations which are substantially free of volatile adjuvants such as a saturated hydrocarbon, for example propane, n-butane, isobutane, pentane and isopentane, or a dialkyl ether for example dimethyl ether, are preferred.

[0014] The formulations of the invention may be prepared by dispersal of the medicament in the propellant in an appropriate container, e.g. with the aid of sonication. The process is desirably carried out under anhydrous conditions to obviate any adverse effects of moisture on suspension stability.

[0015] The formulations according to the invention form weakly flocculated suspensions on standing but, surprisingly, these suspensions have been found to be easily redispersed by mild agitation to provide suspensions with excellent delivery characteristics suitable for use in pressurised inhalers, even after prolonged storage. Avoiding the use of formulation excipients e.g. surfactants, cosolvents etc in the aerosol formulations according to the invention is also advantageous since the formulations may be substantially taste and odour free, less irritant and less toxic than conventional formulations.

[0016] The chemical and physical stability and the pharmaceutical acceptability of the aerosol formulations according to the invention may be determined by techniques well known to those skilled in the art. Thus, for example, the chemical stability of the components may be determined by HPLC assay, for example, after prolonged storage of the product. Physical stability data may be gained from other conventional analytical techniques such as, for example, by leak testing, by valve delivery assay (average shot weights per actuation), by dose reproducibility assay (active ingredient per actuation) and spray distribution analysis.

[0017] The particle size distribution of the aerosol formulations according to the invention is particularly impressive and may be measured by conventional techniques, for example by cascade impaction or by the "Twin Impinger" analytical process. As used herein reference to the "Twin Impinger" assay means "Determination of the deposition of the emitted dose in pressurised inhalations using apparatus A" as defined in British Pharmacopoeia 1988, pages A204-207, Appendix XVII C. Such techniques enable the "respirable fraction" of the aerosol formulations to be calculated. As used herein reference to "respirable fraction" means the amount of active ingredient collected in the lower impingement chamber per actuation expressed as a percentage of the total amount of active ingredient delivered per actuation using the twin impinger method described above. The formulations according to the invention have been found to have a respirable fraction of 20% or more by weight of the medicament, preferably 25 to 70%, for example 30 to 60%.

[0018] The formulations for use in the invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters generally com-

prise a container capable of withstanding the vapour pressure of the propellant such as a plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber and neoprene. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (e.g. DF10, DF30, DF60), Bepak plc, UK (e.g. BK300, BK356) and 3M-Neotechnic Ltd, UK (e.g. Spraymiser™).

[0019] Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled canisters. Thus, for example, in one bulk manufacturing method a metering valve is crimped onto an aluminium can to form an empty canister. The particulate medicament is added to a charge vessel and liquified propellant is pressure filled through the charge vessel into a manufacturing vessel. The drug suspension is mixed before recirculation to a filling machine and an aliquot of the drug suspension is then filled through the metering valve into the canister. Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing.

[0020] Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient e.g. a mouthpiece actuator. Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or "puff", for example in the range of 10 to 5000 microgram medicament per puff.

[0021] Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. It will be appreciated that the precise dose administered will depend on the age and condition of the patient and the frequency of administration and will ultimately be at the discretion of the attendant physician. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.

[0022] Suitable daily doses, may be, for example in the range 50 to 2000 microgram of fluticasone propionate depending on the severity of the disease.

5

EP 0 990 437 B1

6

[0023] Thus, for example, each valve actuation may deliver 25, 50, 125 or 250 microgram fluticasone propionate. Typically each filled canister for use in a metered dose inhaler contains 100, 160 or 240 metered doses or puffs of medicament.

[0024] Respiratory disorders such as, for example, asthma, can be treated by the administration by inhalation of an effective amount of a formulation as herein described.

[0025] The following non-limitative Examples serve to illustrate the invention.

Example 1

[0026] Micronised fluticasone propionate (24mg) was weighed into a clean, dry, plastic-coated glass bottle and 1,1,1,2-tetrafluoroethane (18.2g) was added from a vacuum flask. The bottle was quickly sealed with a blank aluminium ferrule. The resulting aerosol contained 0.132% w/w fluticasone propionate.

Examples 2 and 3

[0027] Micronised fluticasone propionate (66mg or 6.6mg) was weighed directly into each of 100 open aluminium cans and a metering valve was then crimped into place on each can. 1,1,1,2-Tetrafluoroethane (18.2g) was then added to each canister under pressure, through the valve, and each filled canister shaken to disperse the drug. The resulting inhalers contained 66 or 6.6mg fluticasone propionate and delivered 250 or 25 microgram fluticasone propionate per actuation (Examples 2 and 3 respectively).

Claims

1. A pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation **characterised in that** it consists essentially of particulate fluticasone propionate as medicament, and 1,1,1,2-tetrafluoroethane as propellant, and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
2. A pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation **characterised in that** it consists of particulate fluticasone propionate and 1,1,1,2-tetrafluoroethane, wherein said fluticasone propionate is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
3. A pharmaceutical aerosol formulation according to claim 2 wherein fluticasone propionate is present in the formulation at a concentration of 0.132% w/w.

4. A pharmaceutical aerosol formulation according to claim 2 wherein fluticasone propionate is present in the formulation in an amount of 66mg per 18.2g of 1,1,1,2-tetrafluoroethane.
5. A pharmaceutical aerosol formulation according to claim 2 wherein fluticasone propionate is present in the formulation in an amount of 6.6mg per 18.2g of 1,1,1,2-tetrafluoroethane.
6. A pharmaceutical aerosol formulation according to any one of claims 1 to 5 wherein the use is use in the treatment of respiratory disorders.
7. A pharmaceutical aerosol formulation according to claim 6 wherein the respiratory disorder is asthma.
8. The use of a pharmaceutical aerosol formulation **characterised in that** it consists essentially of particulate fluticasone propionate as medicament, and 1,1,1,2-tetrafluoroethane as propellant, and that the formulation is free of surfactant, for the manufacture of a medicament for administration by inhalation, wherein said medicament is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
9. The use of a pharmaceutical aerosol formulation **characterised in that** it consists of particulate fluticasone propionate and 1,1,1,2-tetrafluoroethane, for the manufacture of a medicament for administration by inhalation, wherein said fluticasone propionate is present in an amount of 0.01 to 1% w/w relative to the total weight of the formulation.
10. Use according to claim 9 wherein fluticasone propionate is present in the formulation at a concentration of 0.132% w/w.
11. Use according to claim 9 wherein fluticasone propionate is present in the formulation in an amount of 66mg per 18.2g of 1,1,1,2-tetrafluoroethane.
12. Use according to claim 9 wherein fluticasone propionate is present in the formulation in an amount of 6.6mg per 18.2g of 1,1,1,2-tetrafluoroethane.
13. The use according to any one of claims 8 to 12 wherein the use is use in the treatment of respiratory disorders.
14. The use according to claim 13 wherein the respiratory disorder is asthma.
15. A canister comprising a container closed with a metering valve which contains a pharmaceutical aerosol formulation according to any one of claims 1 to 7.

7

EP 0 990 437 B1

8

16. A canister according to claim 15 wherein the container is an aluminium can.
17. A canister according to claim 16 wherein the aluminium can is anodised, lacquer coated and/or plastic coated.
18. A process for preparing a pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation **characterised in that** it consists essentially of particulate fluticasone propionate as medicament, and 1,1,1,2-tetrafluoroethane as propellant, and that the formulation is free of surfactant, wherein said medicament is present in an amount of 0.01-1% w/w relative to the total weight of the formulation, which process comprises dispersing the medicament in the propellant.
19. A process for preparing a pharmaceutical aerosol formulation for use in the administration of medicaments by inhalation **characterised in that** it consists of particulate fluticasone propionate and 1,1,1,2-tetrafluoroethane, wherein said fluticasone propionate is present in an amount of 0.01-1% w/w relative to the total weight of the formulation, which process comprises dispersing the fluticasone propionate in the 1,1,1,2-tetrafluoroethane.
20. A process according to claim 19 wherein fluticasone propionate is present in the formulation at a concentration of 0.132% w/w.
21. A process according to claim 19 wherein fluticasone propionate is present in the formulation in an amount of 66mg per 18.2g of 1,1,1,2-tetrafluoroethane.
22. A process according to claim 19 wherein fluticasone propionate is present in the formulation in an amount of 6.6mg per 18.2g of 1,1,1,2-tetrafluoroethane.

Patentansprüche

1. Pharmazeutische Aerosolformulierung zur Verwendung in der Verabreichung von Medikamenten durch Inhalation, **dadurch gekennzeichnet, daß** sie im wesentlichen aus teilchenförmigem Fluticasonpropionat als Medikament und 1,1,1,2-Tetrafluorethan als Treibmittel besteht, und daß die Formulierung frei von Tensid ist, worin das Medikament in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung vorhanden ist.
2. Pharmazeutische Aerosolformulierung zur Verwendung in der Verabreichung von Medikamenten durch Inhalation, **dadurch gekennzeichnet, daß**

sie aus teilchenförmigem Fluticasonpropionat und 1,1,1,2-Tetrafluorethan besteht, worin das Fluticasonpropionat in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung

3. Pharmazeutische Aerosolformulierung gemäß Anspruch 2, worin Fluticasonpropionat in der Formulierung in einer Konzentration von 0,132 % G/G vorhanden ist.
4. Pharmazeutische Aerosolformulierung gemäß Anspruch 2, worin Fluticasonpropionat in der Formulierung in einer Menge von 66 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhanden ist.
5. Pharmazeutische Aerosolformulierung gemäß Anspruch 2, worin Fluticasonpropionat in der Formulierung in einer Menge von 6,6 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhanden ist.
6. Pharmazeutische Aerosolformulierung gemäß einem der Ansprüche 1 bis 5, worin die Verwendung die Verwendung in der Behandlung von Atemwegsstörungen ist.
7. Pharmazeutische Aerosolformulierung gemäß Anspruch 6, worin die Atemwegsstörung Asthma ist.
8. Verwendung einer pharmazeutischen Aerosolformulierung, **dadurch gekennzeichnet, daß** sie im wesentlichen aus teilchenförmigem Fluticasonpropionat als Medikament und 1,1,1,2-Tetrafluorethan als Treibmittel besteht, und daß die Formulierung frei von Tensid ist, zur Herstellung eines Medikaments zur Verabreichung durch Inhalation, worin das Medikament in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung vorhanden ist.
9. Verwendung einer pharmazeutischen Aerosolformulierung, **dadurch gekennzeichnet, daß** sie aus teilchenförmigem Fluticasonpropionat und 1,1,1,2-Tetrafluorethan besteht, zur Herstellung eines Medikaments zur Verabreichung durch Inhalation, worin das Fluticasonpropionat in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung vorhanden ist.
10. Verwendung gemäß Anspruch 9, worin Fluticasonpropionat in der Formulierung in einer Konzentration von 0,132 % G/G vorhanden ist.
11. Verwendung gemäß Anspruch 9, worin Fluticasonpropionat in der Formulierung in einer Menge von 66 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhanden ist.
12. Verwendung gemäß Anspruch 9, worin Fluticason-

9

EP 0 990 437 B1

10

propionat in der Formulierung in einer Menge von 6,6 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhanden ist.

den ist.

13. Verwendung gemäß einem der Ansprüche 8 bis 12, worin die Verwendung die Verwendung in der Behandlung von Atemwegsstörungen ist.

14. Verwendung gemäß Anspruch 13, worin die Atemwegsstörung Asthma ist.

15. Kanister, umfassend einen mit einem Dosierventil verschlossenen Behälter, der eine pharmazeutische Aerosolformulierung gemäß einem der Ansprüche 1 bis 7 enthält.

16. Kanister gemäß Anspruch 15, worin der Behälter eine Aluminiumdose ist.

17. Kanister gemäß Anspruch 16, worin das Aluminium eloxiert, lackiert und/oder kunststoffbeschichtet ist.

18. Verfahren zur Herstellung einer pharmazeutischen Aerosolformulierung zur Verwendung in der Verabreichung von Medikamenten durch Inhalation, **dadurch gekennzeichnet, daß** sie im wesentlichen aus teilchenförmigem Fluticasonpropionat als Medikament und 1,1,1,2-Tetrafluorethan als Treibmittel besteht, und daß die Formulierung frei von Tensid ist, worin das Medikament in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung vorhanden ist, wobei das Verfahren das Dispergieren des Medikaments im Treibmittel umfaßt.

19. Verfahren zur Herstellung einer pharmazeutischen Aerosolformulierung zur Verwendung in der Verabreichung von Medikamenten durch Inhalation, **dadurch gekennzeichnet, daß** sie aus teilchenförmigem Fluticasonpropionat und 1,1,1,2-Tetrafluorethan besteht, worin das Fluticasonpropionat in einer Menge von 0,01 bis 1 % G/G relativ zum Gesamtgewicht der Formulierung vorhanden ist, wobei das Verfahren das Dispergieren des Fluticasonpropionats im 1,1,1,2-Tetrafluorethan umfaßt.

20. Verfahren gemäß Anspruch 19, worin Fluticasonpropionat in der Formulierung in einer Konzentration von 0,132 % G/G vorhanden ist.

21. Verfahren gemäß Anspruch 19, worin Fluticasonpropionat in der Formulierung in einer Menge von 66 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhanden ist.

22. Verfahren gemäß Anspruch 19, worin Fluticasonpropionat in der Formulierung in einer Menge von 6,6 mg auf 18,2 g 1,1,1,2-Tetrafluorethan vorhan-

Revendications

1. Formulation pharmaceutique sous forme d'aérosol utile dans l'administration de médicaments par inhalation, **caractérisée en ce qu'elle** consiste essentiellement en propionate de fluticasone particulière en tant que médicament, et en 1,1,1,2-tétrafluoroéthane en tant qu'agent propulseur, et que la formulation est dépourvue de tensioactif, dans laquelle ledit médicament est présent en une quantité de 0,01 à 1% en poids/poids par rapport au poids total de la formulation.

2. Formulation pharmaceutique sous forme d'aérosol utile dans l'administration de médicaments par inhalation, **caractérisée en ce qu'elle** consiste en propionate de fluticasone particulière et en 1,1,1,2-tétrafluoroéthane, dans laquelle ledit propionate de fluticasone est présent en une quantité de 0,01 à 1% en poids/poids par rapport au poids total de la formulation.

3. Formulation pharmaceutique sous forme d'aérosol suivant la revendication 2, dans laquelle le propionate de fluticasone est présent dans la formulation à une concentration de 0,132% en poids/poids.

4. Formulation pharmaceutique sous forme d'aérosol suivant la revendication 2, dans laquelle le propionate de fluticasone est présent dans la formulation en une quantité de 66 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane.

5. Formulation pharmaceutique sous forme d'aérosol suivant la revendication 2, dans laquelle le propionate de fluticasone est présent dans la formulation en une quantité de 6,6 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane.

6. Formulation pharmaceutique sous forme d'aérosol suivant l'une quelconque des revendications 1 à 5, dans laquelle l'utilisation est une utilisation dans le traitement de troubles respiratoires.

7. Formulation pharmaceutique sous forme d'aérosol suivant la revendication 6, dans laquelle le trouble respiratoire est l'asthme.

8. Utilisation d'une formulation pharmaceutique sous forme d'aérosol, **caractérisée en ce qu'elle** consiste essentiellement en propionate de fluticasone particulière en tant que médicament, et en 1,1,1,2-tétrafluoroéthane en tant qu'agent propulseur, et que la formulation est dépourvue de tensioactif, pour la fabrication d'un médicament pour

11

EP 0 990 437 B1

12

l'administration par inhalation, dans laquelle ledit médicament est présent en une quantité de 0,01 à 1% en poids/poids par rapport au poids total de la formulation.

9. Utilisation d'une formulation pharmaceutique sous forme d'aérosol, **caractérisée en ce qu'elle** consiste en propionate de fluticasone particulaire et en 1,1,1,2-tétrafluoroéthane pour la fabrication d'un médicament pour l'administration par inhalation, dans laquelle ledit propionate de fluticasone est présent en une quantité de 0,01 à 1% en poids/poids par rapport au poids total de la formulation. 5
10. Utilisation suivant la revendication 9, dans laquelle le propionate de fluticasone est présent dans la formulation à une concentration de 0,132% en poids/poids. 10
11. Utilisation suivant la revendication 9, dans laquelle le propionate de fluticasone est présent dans la formulation en une quantité de 66 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane 15
12. Utilisation suivant la revendication 9, dans laquelle le propionate de fluticasone est présent dans la formulation en une quantité de 6,6 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane. 20
13. Utilisation suivant l'une quelconque des revendications 8 à 12, dans laquelle l'utilisation est une utilisation dans le traitement de troubles respiratoires. 25
14. Utilisation suivant la revendication 13, dans laquelle le trouble respiratoire est l'asthme. 30
15. Récipient comprenant un réservoir fermé par une vanne doseuse qui contient une formulation pharmaceutique sous forme d'aérosol suivant l'une quelconque des revendications 1 à 7. 35
16. Récipient suivant la revendication 15, dans laquelle le réservoir est une boîte en aluminium. 40
17. Récipient suivant la revendication 16, dans laquelle la boîte d'aluminium est anodisée, revêtue de laque et/ou revêtue de matière plastique. 45
18. Procédé pour la préparation d'une formulation pharmaceutique sous forme d'aérosol utile dans l'administration de médicaments par inhalation, **caractérisé en ce qu'elle** consiste essentiellement en propionate de fluticasone en tant que médicament, et en 1,1,1,2-tétrafluoroéthane en tant qu'agent propulseur, et que la formulation est dépourvue de tensioactif, dans laquelle ledit médicament est présent en une quantité de 0,01 à 1% -en poids/poids par rapport au poids total de la formulation, lequel pro- 50

cédé comprend la dispersion du médicament dans l'agent propulseur.

19. Procédé pour la préparation d'une formulation pharmaceutique sous forme d'aérosol utile dans l'administration de médicaments par inhalation, **caractérisé en ce qu'elle** consiste en propionate de fluticasone particulaire et en 1,1,1,2-tétrafluoroéthane, dans laquelle ledit propionate de fluticasone est présent en une quantité de 0,01 à 1% en poids/poids par rapport au poids total de la formulation, lequel procédé comprend la dispersion du propionate de fluticasone dans le 1,1,1,2-tétrafluoroéthane. 55
20. Procédé suivant la revendication 19, dans lequel le propionate de fluticasone est présent dans la formulation à une concentration de 0,132% en poids/poids.
21. Procédé suivant la revendication 19, dans lequel le propionate de fluticasone est présent dans la formulation en une quantité de 66 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane.
22. Procédé suivant la revendication 19, dans lequel le propionate de fluticasone est présent dans la formulation en une quantité de 6,6 mg pour 18,2 g de 1,1,1,2-tétrafluoroéthane.